Changes in Muscarinic M2 Receptor Levels in the Cortex of Subjects with Bipolar Disorder and Major Depressive Disorder and in Rats after Treatment with Mood Stabilisers and Antidepressants
Andrew Stuart Gibbons, Won Je Jeon, Elizabeth Scarr, Brian Dean
International Journal of Neuropsychopharmacology | OXFORD UNIV PRESS | Published : 2016
Awarded by National Health and Medical research Council
Awarded by Australian Research Council (ARC)
The authors would like to thank Geoff Pavey for his contribution to preparing the human CNS tissue, Nahed Tawadros for hers in drug treating the rats in this study and Chris Felder (Eli Lilly) for providing the CHRM2 knockout mice. The fluoxetine used in this study was gifted by Eli Lilly. The authors acknowledge the Victorian Brain Bank Network which is supported by the Florey Institute for Neuroscience and Mental Health, the Alfred Hospital, the Victorian Forensic Institute of Medicine, the University of Melbourne and funded by Australia's National Health & Medical Research Council, Helen Macpherson Smith Trust, Parkinson's Victoria and Perpetual Philanthropic Services.This work was supported by the National Health and Medical research Council (BD Senior Research Fellow: APP1002240; Project Grants: 628699 and APP 1066144), the Australian Research Council (ES: ARC Future Fellowship FT100100689), the University of Melbourne (WJ: University of Melbourne International Postgraduate Award) and the Victorian Government's Operational Infrastructure Support.